The following is a summary of “Does Weight Reduction Drive the Reduction in Blood Pressure in People Living With Obesity Treated With Tirzepatide?: Insights From SURMOUNT-1 Study,” published in the November 2023 issue of Cardiology by Sattar et al.
Tirzepatide (TZP) is a medication being studied for weight management and treatment of type 2 diabetes. In a clinical trial, this effectively reduced body weight, blood pressure, and diastolic blood pressure. Researchers aimed to determine if weight loss mediates the effect of TZP on blood pressure reduction.
The study included adults with a BMI ≥30 kg/m2, or ≥27 kg/m2 with at least one diagnosed weight-related complication (excluding diabetes), who were administered TZP(5, 10, or 15 mg) or placebo(PBO) over 72 weeks. Patients(pts) with a valid baseline BP value and at least one post-baseline value were included using the efficacy analysis set (excluding off-treatment data). Changes in systolic(SBP) and diastolic(DBP) from baseline to 72 weeks were compared between pooled TZP doses and PBO using mixed models for repeated measures (MMRM) stratified by baseline BP levels. The proportion of pts achieving recommended BP thresholds was assessed. Post-hoc mediation analysis explored the weight-loss dependent and independent effects of TZP on SBP and DBP reduction.
In the pooled analysis, regardless of baseline blood pressure values, TZP consistently reduced SBP and DBP blood pressure at 72 weeks compared to PBO. At this point, a higher percentage of TZP-treated participants achieved recommended SBP and DBP levels than those on PBO, almost doubling the proportion of pts with normal blood pressure. Changes in body weight were moderately correlated with reductions in SBP (r=0.24) and DBP (r=0.24). Mediation analysis revealed that most SBP and DBP reductions were primarily mediated through weight loss (77% and 99%, respectively).
The study found that TZP effectively lowered blood pressure and helped more patients reach normal levels, mainly through weight loss.
Source: abstractsonline.com/pp8/#!/10871/presentation/11944
